Drug Profile
Recombinant exendin 4 - Uni-Bio Science Group
Alternative Names: Recombinant exendin-4 - Uni-Bio Science Group; Uni rE4; Uni-E4; Uni-E4-FcLatest Information Update: 21 Oct 2021
Price :
$50
*
At a glance
- Originator Uni-Bio Science Group
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Oct 2021 Discontinued - Phase-I for Type 2 diabetes mellitus in China (SC) (Uni-Bio Science Group pipeline, October 2021)
- 21 Oct 2021 Discontinued - Phase-III for Type 2 diabetes mellitus in China (SC) (Uni-Bio Science Group pipeline, October 2021)
- 22 Aug 2018 Uni-Bio Science Group plans a phase III trial for Type-2 diabetes mellitus first half of 2019